CDX2 - Revision history

Michael at 22:41, 27 January 2023

2023-01-27T22:41:08Z

← Older revision		Revision as of 22:41, 27 January 2023
Line 26:		Line 26:
	*Intestinal adenocarcinomas.		*Intestinal adenocarcinomas.
	**[[Colorectal adenocarcinoma]] ~ 90% of cases.<ref name=pmid13679455/>		**[[Colorectal adenocarcinoma]] ~ 90% of cases.<ref name=pmid13679455/>
			*[[Neuroendocrine tumours]].<ref name=pmid15640551>{{cite journal \|authors=Erickson LA, Papouchado B, Dimashkieh H, Zhang S, Nakamura N, Lloyd RV \|title=Cdx2 as a marker for neuroendocrine tumors of unknown primary sites \|journal=Endocr Pathol \|volume=15 \|issue=3 \|pages=247–52 \|date=2004 \|pmid=15640551 \|doi=10.1385/ep:15:3:247 \|url=}}</ref>

	====Sometimes positive====		====Sometimes positive====

Michael: /* Negative */

2018-07-31T14:32:17Z

Negative

← Older revision		Revision as of 14:32, 31 July 2018
Line 36:		Line 36:

	===Negative===		===Negative===
	*[[Lung adenocarcinoma]] -ve (<5% +ve in 20 cases<ref name=pmid17549351>{{Cite journal \| last1 = Tanaka \| first1 = S. \| last2 = Saito \| first2 = K. \| last3 = Ito \| first3 = T. \| last4 = Tajima \| first4 = K. \| last5 = Mogi \| first5 = A. \| last6 = Shitara \| first6 = Y. \| last7 = Sano \| first7 = T. \| last8 = Kuwano \| first8 = H. \| title = CDX2 as a useful marker of colorectal adenocarcinoma metastases to lung in pre-operative biopsy specimens. \| journal = Oncol Rep \| volume = 18 \| issue = 1 \| pages = 87-92 \| month = Jul \| year = 2007 \| doi = \| PMID = 17549351 }}</ref>).		*[[Lung adenocarcinoma]] -ve.
			**<5% +ve in 20 cases.<ref name=pmid17549351>{{Cite journal \| last1 = Tanaka \| first1 = S. \| last2 = Saito \| first2 = K. \| last3 = Ito \| first3 = T. \| last4 = Tajima \| first4 = K. \| last5 = Mogi \| first5 = A. \| last6 = Shitara \| first6 = Y. \| last7 = Sano \| first7 = T. \| last8 = Kuwano \| first8 = H. \| title = CDX2 as a useful marker of colorectal adenocarcinoma metastases to lung in pre-operative biopsy specimens. \| journal = Oncol Rep \| volume = 18 \| issue = 1 \| pages = 87-92 \| month = Jul \| year = 2007 \| doi = \| PMID = 17549351 }}</ref>
			**~12% of 93 cases +ve, all positive cases TTF-1 +ve and napsin A +ve.<ref name=pmid26469326>{{Cite journal \| last1 = Cowan \| first1 = ML. \| last2 = Li \| first2 = QK. \| last3 = Illei \| first3 = PB. \| title = CDX-2 Expression in Primary Lung Adenocarcinoma. \| journal = Appl Immunohistochem Mol Morphol \| volume = 24 \| issue = 1 \| pages = 16-9 \| month = Jan \| year = 2016 \| doi = 10.1097/PAI.0000000000000250 \| PMID = 26469326 }}</ref>
	*[[Choroid plexus papilloma]]s -ve (0 in 65 cases<ref name=pmid19795349>{{Cite journal \| last1 = Beschorner \| first1 = R. \| last2 = Mittelbronn \| first2 = M. \| last3 = Mugler \| first3 = M. \| last4 = Meyermann \| first4 = R. \| last5 = Schittenhelm \| first5 = J. \| title = Immunohistochemical analysis of CDX2 expression in normal choroid plexus epithelium and choroid plexus tumors. \| journal = Histol Histopathol \| volume = 24 \| issue = 12 \| pages = 1507-14 \| month = Dec \| year = 2009 \| doi = \| PMID = 19795349 }}</ref>).		*[[Choroid plexus papilloma]]s -ve (0 in 65 cases<ref name=pmid19795349>{{Cite journal \| last1 = Beschorner \| first1 = R. \| last2 = Mittelbronn \| first2 = M. \| last3 = Mugler \| first3 = M. \| last4 = Meyermann \| first4 = R. \| last5 = Schittenhelm \| first5 = J. \| title = Immunohistochemical analysis of CDX2 expression in normal choroid plexus epithelium and choroid plexus tumors. \| journal = Histol Histopathol \| volume = 24 \| issue = 12 \| pages = 1507-14 \| month = Dec \| year = 2009 \| doi = \| PMID = 19795349 }}</ref>).
	*[[Pituitary adenoma]] & [[Craniopharyngioma]] (0 in 75 and 0 in 23 cases <ref name=pmid20602288> {{Cite journal \| last1 = Schittenhelm \| first1 = J. \| last2 = Psaras \| first2 = T. \| last3 = Meyermann \| first3 = R. \| last4 = Honegger \| first4 = J. \| last5 = Beschorner \| first5 = R. \| title = Pituitary adenomas and craniopharyngiomas are CDX2 negative neoplasms. \| journal = Folia Neuropathol \| volume = 48 \| issue = 2 \| pages = 75-80 \| month = \| year = 2010 \| doi = \| PMID = 20602288 }}</ref>).		*[[Pituitary adenoma]] & [[Craniopharyngioma]] (0 in 75 and 0 in 23 cases <ref name=pmid20602288> {{Cite journal \| last1 = Schittenhelm \| first1 = J. \| last2 = Psaras \| first2 = T. \| last3 = Meyermann \| first3 = R. \| last4 = Honegger \| first4 = J. \| last5 = Beschorner \| first5 = R. \| title = Pituitary adenomas and craniopharyngiomas are CDX2 negative neoplasms. \| journal = Folia Neuropathol \| volume = 48 \| issue = 2 \| pages = 75-80 \| month = \| year = 2010 \| doi = \| PMID = 20602288 }}</ref>).

Michael: /* Pathology */

2016-01-28T19:41:13Z

Pathology

← Older revision		Revision as of 19:41, 28 January 2016
Line 32:		Line 32:
	*[[Ovarian mucinous adenocarcinoma]]<ref name=pmid14668551/> ~20-30% of cases.<ref name=pmid13679455/>		*[[Ovarian mucinous adenocarcinoma]]<ref name=pmid14668551/> ~20-30% of cases.<ref name=pmid13679455/>
	*[[Endometrioid endometrial adenocarcinoma]] ~20-30% of cases.<ref name=pmid13679455/>		*[[Endometrioid endometrial adenocarcinoma]] ~20-30% of cases.<ref name=pmid13679455/>

	~~===Negative or positive===~~
	*[[Yolk sac tumour]] (8 +ve of 20 cases<ref name=pmid19578052>{{Cite journal \| last1 = Bing \| first1 = Z. \| last2 = Pasha \| first2 = T. \| last3 = Tomaszewski \| first3 = JE. \| last4 = Zhang \| first4 = P. \| title = CDX2 expression in yolk sac component of testicular germ cell tumors. \| journal = Int J Surg Pathol \| volume = 17 \| issue = 5 \| pages = 373-7 \| month = Oct \| year = 2009 \| doi = 10.1177/1066896909338598 \| PMID = 19578052 }}</ref>).		*[[Yolk sac tumour]] (8 +ve of 20 cases<ref name=pmid19578052>{{Cite journal \| last1 = Bing \| first1 = Z. \| last2 = Pasha \| first2 = T. \| last3 = Tomaszewski \| first3 = JE. \| last4 = Zhang \| first4 = P. \| title = CDX2 expression in yolk sac component of testicular germ cell tumors. \| journal = Int J Surg Pathol \| volume = 17 \| issue = 5 \| pages = 373-7 \| month = Oct \| year = 2009 \| doi = 10.1177/1066896909338598 \| PMID = 19578052 }}</ref>).
	*[[Small bowel]] adenocarcinoma +ve/-ve (~43% +ve in series of 189 cases<ref name=pmid24603585>{{Cite journal \| last1 = Jun \| first1 = SY. \| last2 = Eom \| first2 = DW. \| last3 = Park \| first3 = H. \| last4 = Bae \| first4 = YK. \| last5 = Jang \| first5 = KT. \| last6 = Yu \| first6 = E. \| last7 = Hong \| first7 = SM. \| title = Prognostic significance of CDX2 and mucin expression in small intestinal adenocarcinoma. \| journal = Mod Pathol \| volume = \| issue = \| pages = \| month = Mar \| year = 2014 \| doi = 10.1038/modpathol.2014.36 \| PMID = 24603585 }}</ref>).		*[[Small bowel]] adenocarcinoma +ve/-ve (~43% +ve in series of 189 cases<ref name=pmid24603585>{{Cite journal \| last1 = Jun \| first1 = SY. \| last2 = Eom \| first2 = DW. \| last3 = Park \| first3 = H. \| last4 = Bae \| first4 = YK. \| last5 = Jang \| first5 = KT. \| last6 = Yu \| first6 = E. \| last7 = Hong \| first7 = SM. \| title = Prognostic significance of CDX2 and mucin expression in small intestinal adenocarcinoma. \| journal = Mod Pathol \| volume = \| issue = \| pages = \| month = Mar \| year = 2014 \| doi = 10.1038/modpathol.2014.36 \| PMID = 24603585 }}</ref>).

Michael: /* Positive */

2016-01-28T19:40:35Z

Positive

← Older revision		Revision as of 19:40, 28 January 2016
Line 24:		Line 24:
	==Pathology==		==Pathology==
	===Positive===		===Positive===
	*Intestinal adenocarcinomas - ~~esp~~. [[~~colorectal~~ adenocarcinoma]].		*Intestinal adenocarcinomas.
	*[[Ovarian mucinous adenocarcinoma]] ~~+ve~~.<ref name=~~pmid14668551~~/>		**[[Colorectal adenocarcinoma]] ~ 90% of cases.<ref name=pmid13679455/>

			====Sometimes positive====
			*[[Stomach adenocarcinoma]] ~20-30% of cases.<ref name=pmid13679455/>
			*[[Esophageal adenocarcinoma]] ~20-30% of cases.<ref name=pmid13679455/>
			*[[Ovarian mucinous adenocarcinoma]]<ref name=pmid14668551/> ~20-30% of cases.<ref name=pmid13679455/>
			*[[Endometrioid endometrial adenocarcinoma]] ~20-30% of cases.<ref name=pmid13679455/>

	===Negative or positive===		===Negative or positive===

Michael: /* Normal */

2016-01-28T19:38:05Z

Normal

← Older revision		Revision as of 19:38, 28 January 2016
Line 19:		Line 19:
	==Normal==		==Normal==
	*Intestinal epithelium.<ref name=pmid14668551>{{Cite journal \| last1 = Groisman \| first1 = GM. \| last2 = Meir \| first2 = A. \| last3 = Sabo \| first3 = E. \| title = The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries. \| journal = Int J Gynecol Pathol \| volume = 23 \| issue = 1 \| pages = 52-7 \| month = Jan \| year = 2004 \| doi = 10.1097/01.pgp.0000101141.31270.a0 \| PMID = 14668551 }}</ref>		*Intestinal epithelium.<ref name=pmid14668551>{{Cite journal \| last1 = Groisman \| first1 = GM. \| last2 = Meir \| first2 = A. \| last3 = Sabo \| first3 = E. \| title = The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries. \| journal = Int J Gynecol Pathol \| volume = 23 \| issue = 1 \| pages = 52-7 \| month = Jan \| year = 2004 \| doi = 10.1097/01.pgp.0000101141.31270.a0 \| PMID = 14668551 }}</ref>
			*Pancreatic ducts.<ref name=pmid13679455>{{Cite journal \| last1 = Moskaluk \| first1 = CA. \| last2 = Zhang \| first2 = H. \| last3 = Powell \| first3 = SM. \| last4 = Cerilli \| first4 = LA. \| last5 = Hampton \| first5 = GM. \| last6 = Frierson \| first6 = HF. \| title = Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays. \| journal = Mod Pathol \| volume = 16 \| issue = 9 \| pages = 913-9 \| month = Sep \| year = 2003 \| doi = 10.1097/01.MP.0000086073.92773.55 \| PMID = 13679455 }}
			</ref>

	==Pathology==		==Pathology==

Michael: /* Negative or positive */

2015-10-06T04:28:41Z

Negative or positive

← Older revision		Revision as of 04:28, 6 October 2015
Line 26:		Line 26:

	===Negative or positive===		===Negative or positive===
	*[[Yolk sac tumour]] (8 of 20 cases ~~- versus glypican-3).~~<ref name=pmid19578052>{{Cite journal \| last1 = Bing \| first1 = Z. \| last2 = Pasha \| first2 = T. \| last3 = Tomaszewski \| first3 = JE. \| last4 = Zhang \| first4 = P. \| title = CDX2 expression in yolk sac component of testicular germ cell tumors. \| journal = Int J Surg Pathol \| volume = 17 \| issue = 5 \| pages = 373-7 \| month = Oct \| year = 2009 \| doi = 10.1177/1066896909338598 \| PMID = 19578052 }}</ref>		*[[Yolk sac tumour]] (8 +ve of 20 cases<ref name=pmid19578052>{{Cite journal \| last1 = Bing \| first1 = Z. \| last2 = Pasha \| first2 = T. \| last3 = Tomaszewski \| first3 = JE. \| last4 = Zhang \| first4 = P. \| title = CDX2 expression in yolk sac component of testicular germ cell tumors. \| journal = Int J Surg Pathol \| volume = 17 \| issue = 5 \| pages = 373-7 \| month = Oct \| year = 2009 \| doi = 10.1177/1066896909338598 \| PMID = 19578052 }}</ref>).
	*[[Small bowel]] adenocarcinoma +ve/-ve (~43% +ve in series of 189 cases<ref name=pmid24603585>{{Cite journal \| last1 = Jun \| first1 = SY. \| last2 = Eom \| first2 = DW. \| last3 = Park \| first3 = H. \| last4 = Bae \| first4 = YK. \| last5 = Jang \| first5 = KT. \| last6 = Yu \| first6 = E. \| last7 = Hong \| first7 = SM. \| title = Prognostic significance of CDX2 and mucin expression in small intestinal adenocarcinoma. \| journal = Mod Pathol \| volume = \| issue = \| pages = \| month = Mar \| year = 2014 \| doi = 10.1038/modpathol.2014.36 \| PMID = 24603585 }}</ref>).		*[[Small bowel]] adenocarcinoma +ve/-ve (~43% +ve in series of 189 cases<ref name=pmid24603585>{{Cite journal \| last1 = Jun \| first1 = SY. \| last2 = Eom \| first2 = DW. \| last3 = Park \| first3 = H. \| last4 = Bae \| first4 = YK. \| last5 = Jang \| first5 = KT. \| last6 = Yu \| first6 = E. \| last7 = Hong \| first7 = SM. \| title = Prognostic significance of CDX2 and mucin expression in small intestinal adenocarcinoma. \| journal = Mod Pathol \| volume = \| issue = \| pages = \| month = Mar \| year = 2014 \| doi = 10.1038/modpathol.2014.36 \| PMID = 24603585 }}</ref>).

Jensflorian: /* Negative */ DDx metastatic vs epithelial tumours of the CNS

2015-10-05T09:00:08Z

Negative: DDx metastatic vs epithelial tumours of the CNS

← Older revision		Revision as of 09:00, 5 October 2015
Line 31:		Line 31:
	===Negative===		===Negative===
	*[[Lung adenocarcinoma]] -ve (<5% +ve in 20 cases<ref name=pmid17549351>{{Cite journal \| last1 = Tanaka \| first1 = S. \| last2 = Saito \| first2 = K. \| last3 = Ito \| first3 = T. \| last4 = Tajima \| first4 = K. \| last5 = Mogi \| first5 = A. \| last6 = Shitara \| first6 = Y. \| last7 = Sano \| first7 = T. \| last8 = Kuwano \| first8 = H. \| title = CDX2 as a useful marker of colorectal adenocarcinoma metastases to lung in pre-operative biopsy specimens. \| journal = Oncol Rep \| volume = 18 \| issue = 1 \| pages = 87-92 \| month = Jul \| year = 2007 \| doi = \| PMID = 17549351 }}</ref>).		*[[Lung adenocarcinoma]] -ve (<5% +ve in 20 cases<ref name=pmid17549351>{{Cite journal \| last1 = Tanaka \| first1 = S. \| last2 = Saito \| first2 = K. \| last3 = Ito \| first3 = T. \| last4 = Tajima \| first4 = K. \| last5 = Mogi \| first5 = A. \| last6 = Shitara \| first6 = Y. \| last7 = Sano \| first7 = T. \| last8 = Kuwano \| first8 = H. \| title = CDX2 as a useful marker of colorectal adenocarcinoma metastases to lung in pre-operative biopsy specimens. \| journal = Oncol Rep \| volume = 18 \| issue = 1 \| pages = 87-92 \| month = Jul \| year = 2007 \| doi = \| PMID = 17549351 }}</ref>).
			*[[Choroid plexus papilloma]]s -ve (0 in 65 cases<ref name=pmid19795349>{{Cite journal \| last1 = Beschorner \| first1 = R. \| last2 = Mittelbronn \| first2 = M. \| last3 = Mugler \| first3 = M. \| last4 = Meyermann \| first4 = R. \| last5 = Schittenhelm \| first5 = J. \| title = Immunohistochemical analysis of CDX2 expression in normal choroid plexus epithelium and choroid plexus tumors. \| journal = Histol Histopathol \| volume = 24 \| issue = 12 \| pages = 1507-14 \| month = Dec \| year = 2009 \| doi = \| PMID = 19795349 }}</ref>).
			*[[Pituitary adenoma]] & [[Craniopharyngioma]] (0 in 75 and 0 in 23 cases <ref name=pmid20602288> {{Cite journal \| last1 = Schittenhelm \| first1 = J. \| last2 = Psaras \| first2 = T. \| last3 = Meyermann \| first3 = R. \| last4 = Honegger \| first4 = J. \| last5 = Beschorner \| first5 = R. \| title = Pituitary adenomas and craniopharyngiomas are CDX2 negative neoplasms. \| journal = Folia Neuropathol \| volume = 48 \| issue = 2 \| pages = 75-80 \| month = \| year = 2010 \| doi = \| PMID = 20602288 }}</ref>).

	==References==		==References==

Michael at 04:59, 5 October 2015

2015-10-05T04:59:57Z

← Older revision		Revision as of 04:59, 5 October 2015
Line 31:		Line 31:
	===Negative===		===Negative===
	*[[Lung adenocarcinoma]] -ve (<5% +ve in 20 cases<ref name=pmid17549351>{{Cite journal \| last1 = Tanaka \| first1 = S. \| last2 = Saito \| first2 = K. \| last3 = Ito \| first3 = T. \| last4 = Tajima \| first4 = K. \| last5 = Mogi \| first5 = A. \| last6 = Shitara \| first6 = Y. \| last7 = Sano \| first7 = T. \| last8 = Kuwano \| first8 = H. \| title = CDX2 as a useful marker of colorectal adenocarcinoma metastases to lung in pre-operative biopsy specimens. \| journal = Oncol Rep \| volume = 18 \| issue = 1 \| pages = 87-92 \| month = Jul \| year = 2007 \| doi = \| PMID = 17549351 }}</ref>).		*[[Lung adenocarcinoma]] -ve (<5% +ve in 20 cases<ref name=pmid17549351>{{Cite journal \| last1 = Tanaka \| first1 = S. \| last2 = Saito \| first2 = K. \| last3 = Ito \| first3 = T. \| last4 = Tajima \| first4 = K. \| last5 = Mogi \| first5 = A. \| last6 = Shitara \| first6 = Y. \| last7 = Sano \| first7 = T. \| last8 = Kuwano \| first8 = H. \| title = CDX2 as a useful marker of colorectal adenocarcinoma metastases to lung in pre-operative biopsy specimens. \| journal = Oncol Rep \| volume = 18 \| issue = 1 \| pages = 87-92 \| month = Jul \| year = 2007 \| doi = \| PMID = 17549351 }}</ref>).


	==References==		==References==

Michael at 04:59, 5 October 2015

2015-10-05T04:59:39Z

← Older revision		Revision as of 04:59, 5 October 2015
Line 1:		Line 1:
	[[Image:Thyroid PapillaryCarcinoma CribriformMorularVariant CDX2 HP 13BR***.jpg\|~~thumb\|right~~\|CDX2 immunostaining in ~~a case of~~ [[papillary thyroid carcinoma cribriform morular variant]]. ~~(WC)~~]]		{{ Infobox immunostain
			\| Name = {{PAGENAME}}
			\| Image = Thyroid PapillaryCarcinoma CribriformMorularVariant CDX2 HP 13BR***.jpg
			\| Width =
			\| Caption = CDX2 immunostaining in the [[papillary thyroid carcinoma cribriform morular variant]].
			\| Abbrev = CDX2
			\| Synonyms =
			\| Similar =
			\| Clones =
			\| Use =
			\| Subspecial =
			\| Pattern = nuclear
			\| Positive = colorectal adenocarcinoma, small bowel adenocarcinoma, [[yolk sac tumour]], [[ovarian mucinous adenocarcinoma]]
			\| Negative = [[lung adenocarcinoma]]
			\| Other =
			}}
	'''CDX2''' is a commonly used [[immunostain]] in pathology. It is a nuclear stain.		'''CDX2''' is a commonly used [[immunostain]] in pathology. It is a nuclear stain.

Line 6:		Line 21:

	==Pathology==		==Pathology==
	*Intestinal adenocarcinomas ~~+ve~~.		===Positive===
	**[[~~Colorectal~~ adenocarcinoma]].		*Intestinal adenocarcinomas - esp. [[colorectal adenocarcinoma]].
	**[[Small bowel]] adenocarcinoma +ve/-ve (~43% +ve in series of 189 cases<ref name=pmid24603585>{{Cite journal \| last1 = Jun \| first1 = SY. \| last2 = Eom \| first2 = DW. \| last3 = Park \| first3 = H. \| last4 = Bae \| first4 = YK. \| last5 = Jang \| first5 = KT. \| last6 = Yu \| first6 = E. \| last7 = Hong \| first7 = SM. \| title = Prognostic significance of CDX2 and mucin expression in small intestinal adenocarcinoma. \| journal = Mod Pathol \| volume = \| issue = \| pages = \| month = Mar \| year = 2014 \| doi = 10.1038/modpathol.2014.36 \| PMID = 24603585 }}</ref>).
	*[[Ovarian mucinous adenocarcinoma]] +ve.<ref name=pmid14668551/>		*[[Ovarian mucinous adenocarcinoma]] +ve.<ref name=pmid14668551/>

			===Negative or positive===
			*[[Yolk sac tumour]] (8 of 20 cases - versus glypican-3).<ref name=pmid19578052>{{Cite journal \| last1 = Bing \| first1 = Z. \| last2 = Pasha \| first2 = T. \| last3 = Tomaszewski \| first3 = JE. \| last4 = Zhang \| first4 = P. \| title = CDX2 expression in yolk sac component of testicular germ cell tumors. \| journal = Int J Surg Pathol \| volume = 17 \| issue = 5 \| pages = 373-7 \| month = Oct \| year = 2009 \| doi = 10.1177/1066896909338598 \| PMID = 19578052 }}</ref>
			*[[Small bowel]] adenocarcinoma +ve/-ve (~43% +ve in series of 189 cases<ref name=pmid24603585>{{Cite journal \| last1 = Jun \| first1 = SY. \| last2 = Eom \| first2 = DW. \| last3 = Park \| first3 = H. \| last4 = Bae \| first4 = YK. \| last5 = Jang \| first5 = KT. \| last6 = Yu \| first6 = E. \| last7 = Hong \| first7 = SM. \| title = Prognostic significance of CDX2 and mucin expression in small intestinal adenocarcinoma. \| journal = Mod Pathol \| volume = \| issue = \| pages = \| month = Mar \| year = 2014 \| doi = 10.1038/modpathol.2014.36 \| PMID = 24603585 }}</ref>).

			===Negative===
	*[[Lung adenocarcinoma]] -ve (<5% +ve in 20 cases<ref name=pmid17549351>{{Cite journal \| last1 = Tanaka \| first1 = S. \| last2 = Saito \| first2 = K. \| last3 = Ito \| first3 = T. \| last4 = Tajima \| first4 = K. \| last5 = Mogi \| first5 = A. \| last6 = Shitara \| first6 = Y. \| last7 = Sano \| first7 = T. \| last8 = Kuwano \| first8 = H. \| title = CDX2 as a useful marker of colorectal adenocarcinoma metastases to lung in pre-operative biopsy specimens. \| journal = Oncol Rep \| volume = 18 \| issue = 1 \| pages = 87-92 \| month = Jul \| year = 2007 \| doi = \| PMID = 17549351 }}</ref>).		*[[Lung adenocarcinoma]] -ve (<5% +ve in 20 cases<ref name=pmid17549351>{{Cite journal \| last1 = Tanaka \| first1 = S. \| last2 = Saito \| first2 = K. \| last3 = Ito \| first3 = T. \| last4 = Tajima \| first4 = K. \| last5 = Mogi \| first5 = A. \| last6 = Shitara \| first6 = Y. \| last7 = Sano \| first7 = T. \| last8 = Kuwano \| first8 = H. \| title = CDX2 as a useful marker of colorectal adenocarcinoma metastases to lung in pre-operative biopsy specimens. \| journal = Oncol Rep \| volume = 18 \| issue = 1 \| pages = 87-92 \| month = Jul \| year = 2007 \| doi = \| PMID = 17549351 }}</ref>).
	*[[Yolk sac tumour]] (8 of 20 cases - versus glypican-3).<ref name=pmid19578052>{{Cite journal \| last1 = Bing \| first1 = Z. \| last2 = Pasha \| first2 = T. \| last3 = Tomaszewski \| first3 = JE. \| last4 = Zhang \| first4 = P. \| title = CDX2 expression in yolk sac component of testicular germ cell tumors. \| journal = Int J Surg Pathol \| volume = 17 \| issue = 5 \| pages = 373-7 \| month = Oct \| year = 2009 \| doi = 10.1177/1066896909338598 \| PMID = 19578052 }}</ref>

	==References==		==References==

Michael at 02:44, 31 July 2015

2015-07-31T02:44:21Z

← Older revision		Revision as of 02:44, 31 July 2015
Line 1:		Line 1:
	[[Image:Thyroid PapillaryCarcinoma CribriformMorularVariant CDX2 HP 13BR***.jpg\|thumb\|right\|CDX2 ~~immunostains~~ in a case of [[papillary thyroid carcinoma cribriform morular variant]]. (WC)]]		[[Image:Thyroid PapillaryCarcinoma CribriformMorularVariant CDX2 HP 13BR***.jpg\|thumb\|right\|CDX2 immunostaining in a case of [[papillary thyroid carcinoma cribriform morular variant]]. (WC)]]
	'''CDX2''' is a commonly used [[immunostain]] in pathology. It is a nuclear stain.		'''CDX2''' is a commonly used [[immunostain]] in pathology. It is a nuclear stain.